Abstract
Nineteen evaluable patients with advanced endometrial cancer refractory to one prior chemotherapeutic regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicity was grade 2 or greater leukopenia in 45% of patients. Fludarabine phosphate at this dose and schedule does not appear to be an active agent for patients with refractory endometrial cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 193-194 |
| Number of pages | 2 |
| Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
| Volume | 14 |
| Issue number | 3 |
| DOIs | |
| State | Published - 1991 |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research